Death and disability are often drafted as a single clause with two trigger words, but a disabled shareholder is a living person with ongoing rights, a recovery timeline, and an insurance product built differently from the one that funds a death buyout. Treating them as interchangeable is where most shareholder agreements are thinnest.
Key takeaways
Treadstone Law treats death and disability as related but distinct problems, and devotes a substantial, separate section to disability specifically — because the fact pattern is not the same. A deceased shareholder's shares need to transfer to an estate. A disabled shareholder is still alive, may still hold their shares, may or may not be able to keep working, and may or may not recover. A clause that simply substitutes “disability” for “death” in an otherwise identical provision has not actually addressed any of that.
The starting point is a workable definition: “a clear definition of disability — usually requiring a physician's opinion and specifying a duration.” Without both elements — medical evidence and a time threshold — the clause has no objective moment at which the buyout obligation actually starts, which invites exactly the kind of dispute a well-drafted agreement is supposed to avoid.
The sharpest drafting issue is the line between an illness that resolves and one that does not: “Temporary illness is not the same as permanent disability, and the agreement should be explicit about the threshold.” A shareholder recovering from a six-week medical leave is not the situation a buyout clause should be triggering; “most disability buy-sell insurance products are triggered by total and permanent disability” specifically, which is one reason the underlying insurance product itself tends to enforce a meaningful waiting period before it will pay at all.
Once the trigger is met, the mechanism mirrors what a death clause does — “a purchase mechanism similar to the death clause — mandatory or optional — at a defined price” — which means whatever valuation formula the agreement uses elsewhere should apply here too, rather than leaving disability pricing as its own unresolved question.
Disability buy-sell insurance is its own category, “designed specifically to fund a buyout on disability, usually paying out a lump sum” on total and permanent disability. It is not the same policy, the same underwriting, or the same insurer product line as the life insurance used to fund a death-triggered buyout, and a group that assumes one policy covers both triggers has likely bought neither properly.
Here the two triggers diverge sharply, on the wording of the statute itself. The capital dividend account credit in ITA s.89(1)(d) arises on proceeds a corporation receives “in consequence of the death of any person” — the section's own language ties the credit specifically to a death benefit. A disability payout is, by definition, not a death benefit; the insured person is alive. Reading the section as written, a disability buy-sell payout does not on its face generate the same CDA credit that makes a corporate-redemption death buyout tax-efficient. This is a reading of the fetched statutory text, not a general statement of disability-insurance taxation — the tax treatment of any specific disability policy and payout should be confirmed with an accountant before a group relies on it, but the funding structure should not be assumed to work the same way death-benefit funding does.
A permanent-disability buyout that has already completed does not naturally unwind if the shareholder later recovers — which is exactly why the “total and permanent” threshold, and a meaningful waiting period before the trigger fires, matter as much as the funding mechanism itself. A trigger set too low, or a waiting period set too short, risks forcing a buyout on someone who would otherwise have returned to the business.
The same two-shareholder company, two different triggers
A two-shareholder company's agreement defines disability as inability to perform substantially all of the shareholder's duties for 6 consecutive months, confirmed by an independent physician — an illustrative duration chosen for this example, not a market-standard figure — triggering a mandatory buyout at the agreement's stated valuation formula, funded by a dedicated disability buy-sell policy paying a lump sum on total and permanent disability.
If the same shareholder instead dies, the identical buyout mechanism and the identical valuation formula apply, but the funding source and the tax result change: a corporate-owned life insurance policy pays out, the proceeds are received “in consequence of the death of any person” under s.89(1)(d), and the amount above the policy's adjusted cost basis credits the corporation's capital dividend account. The disability payout, on the statute's own wording, does not have that specific credit available to it — the buyout mechanics converge, but the tax result behind the funding does not.
It should not be. Disability needs its own definition -- usually a physician's opinion plus a specified duration -- its own distinction between temporary and permanent status, and its own funding product, since disability buy-sell insurance is structurally different from the life insurance that funds a death buyout.
Not automatically. The ITA s.89(1)(d) capital dividend account credit is worded to arise on proceeds received 'in consequence of the death of any person' -- a disability payout is not a death benefit on that wording, so the same credit should not be assumed to apply without confirming the specific policy's tax treatment separately.
A completed buyout generally does not unwind on its own if the shareholder later recovers, which is why the agreement's disability definition should require total and permanent disability, confirmed after a meaningful waiting period, rather than triggering on a shorter or more easily met threshold.
It can, and Treadstone Law's guidance treats the disability purchase mechanism as similar to the death clause -- a defined price, mandatory or optional -- which most agreements tie back to whichever single valuation formula governs every trigger, rather than inventing a separate pricing method just for disability.
A 30-minute call is enough to tell you whether AI pays for itself here.
Nobody publishes Canadian transaction data, so every valuation in this country quotes an American benchmark. We are building the Canadian one — multiples, asking-to-sale spreads and days on market, by sector and by city. Leave an email and you will see it first.
No pitch, no listings. One email when the first report lands.
